Sectors
INMB
INmune Bio Inc.
2.30
2 x 1.66
2 x 2.85
bid
ask
-
0.03
1.29%
2 @ 06:54 PM
2.23 -0.07 (2.98%)
| Ytd | 47.44% | |
| 1y | 13.30% |
2.21
day range
2.33
1.09
52 week range
2.50
| Open | 2.32 | Prev Close | 2.33 | Low | 2.21 | High | 2.33 | Mkt Cap | 63.83M |
| Vol | 289.75K | Avg Vol | 728.39K | EPS | -0.62 | P/E | N/A | Forward P/E | -2.23 |
| Beta | 1.85 | Short Ratio | 18.08 | Inst. Own | 24.32% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 10-29 | 50-d Avg | 1.90 | 200-d Avg | 1.58 | 1yr Est | 19.83 |
| Income Statement | |||
| Operating Expenses | 1.48M | ||
| Research and Development Expense | -803.00K | ||
| Selling, General and Administrative Expense | 2.28M | ||
| Operating Income | -1.48M | ||
| Net Income | -1.27M | ||
| Net Income Common Stock | -1.27M | ||
| Net Income Common Stock (USD) | -1.27M | ||
| Consolidated Income | -1.27M | ||
| Earnings per Basic Share | -0.05 | ||
| Earnings per Basic Share (USD) | -0.05 | ||
| Earnings per Diluted Share | -0.05 | ||
| Earning Before Interest & Taxes (EBIT) | -1.27M | ||
| Earning Before Interest & Taxes (USD) | -1.27M | ||
| Weighted Average Shares | 26.72M | ||
| Weighted Average Shares Diluted | 26.72M | ||
| Balance Sheet | |||
| Cash and Equivalents | 18.41M | ||
| Cash and Equivalents (USD) | 18.41M | ||
| Current Assets | 23.80M | ||
| Property, Plant & Equipment Net | 2.51M | ||
| Total Assets | 26.85M | ||
| Debt Current | 812.00K | ||
| Total Debt | 1.41M | ||
| Current Liabilities | 5.89M | ||
| Debt Non-Current | 593.00K | ||
| Total Liabilities | 6.48M | ||
| Accumulated Retained Earnings (Deficit) | -215.72M | ||
| Accumulated Other Comprehensive Income | -823.00K | ||
| Shareholders Equity | 20.36M | ||
| Shareholders Equity (USD) | 20.36M | ||
| Assets Non-Current | 3.05M | ||
| Total Debt (USD) | 1.41M | ||
| Liabilities Non-Current | 593.00K | ||
| Trade and Non-Trade Payables | 5.08M | ||
| Tax Assets | 4.77M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 66.00K | ||
| Net Cash Flow from Financing | 749.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -2.95M | ||
| Issuance (Purchase) of Equity Shares | 35.00K | ||
| Net Cash Flow from Operations | -3.17M | ||
| Effect of Exchange Rate Changes on Cash | -91.00K | ||
| Share Based Compensation | 1.36M | ||